OTCMKTS:NGENF NervGen Pharma (NGENF) Stock Price, News & Analysis $2.65 0.00 (0.00%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesShort InterestBuy This Stock About NervGen Pharma Stock (OTCMKTS:NGENF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NervGen Pharma alerts:Sign Up Key Stats Today's Range$2.60▼$2.7650-Day Range$1.99▼$3.0352-Week Range$1.46▼$5.10Volume23,283 shsAverage Volume128,183 shsMarket Capitalization$163.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview NervGen Pharma Inc. is a clinical‐stage biotechnology company focused on developing novel therapies for injuries and diseases of the nervous system. The company’s chief development program, NVG-291, is a small‐molecule modulator of the protein tyrosine phosphatase receptor sigma (PTPσ), designed to promote nerve repair and functional recovery following central nervous system (CNS) injury. By targeting the molecular pathways that inhibit axon regeneration, NervGen aims to address high‐unmet‐need conditions such as spinal cord injury, multiple sclerosis and stroke. NVG-291 has demonstrated proof‐of‐concept in preclinical models of CNS injury, where treatment resulted in enhanced remyelination and improved motor function. The company has advanced NVG-291 through toxicology studies and initiated a Phase 1 clinical trial in healthy volunteers to evaluate safety and pharmacokinetics. An open‐label, multi‐center Phase 1b/2 trial in patients with acute spinal cord injury is underway, with preliminary results anticipated to guide dose selection and inform future pivotal studies. Founded in 2013 and headquartered in Richmond, British Columbia, NervGen holds an extensive intellectual property portfolio covering its PTPσ‐targeting compounds and methods of use. The company maintains operations in Canada and engagements with research centers in the United States to support its clinical programs. Under the leadership of CEO Ridgely Fisk Green, NervGen has secured strategic partnerships and funding to advance its pipeline toward regulatory milestones and potential out‐licensing or commercialization opportunities.AI Generated. May Contain Errors. Read More Receive NGENF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NervGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGENF Stock News HeadlinesThis Tiny Canadian Stock Could Skyrocket if That Drug Trial SucceedsAugust 26, 2025 | ca.finance.yahoo.comNervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update - Seeking AlphaJuly 9, 2025 | seekingalpha.comReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.September 12 at 2:00 AM | Banyan Hill Publishing (Ad)NervGen Pharma Corp.: NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options UpdateJuly 7, 2025 | finanznachrichten.deNervGen Pharma Updates on Equity Program and Stock OptionsJuly 7, 2025 | tipranks.comNervGen Pharma (NGENF) Gets a Buy from Raymond JamesJune 13, 2025 | theglobeandmail.comNervGen Pharma-Aktie stürzt nach Ergebnissen klinischer Studie abJune 2, 2025 | de.investing.comNervGen Pharma stock tumbles following clinical trial resultsJune 2, 2025 | in.investing.comSee More Headlines NGENF Stock Analysis - Frequently Asked Questions How have NGENF shares performed this year? NervGen Pharma's stock was trading at $2.18 at the start of the year. Since then, NGENF shares have increased by 21.6% and is now trading at $2.65. How do I buy shares of NervGen Pharma? Shares of NGENF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/12/2025Next Earnings (Estimated)11/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:NGENF CIKN/A WebN/A Phone(778) 731-1711FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.07 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.14% Return on Assets-56.59% Debt Debt-to-Equity Ratio0.04 Current Ratio11.21 Quick Ratio11.21 Sales & Book Value Annual Sales$150 thousand Price / Sales1,091.27 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares61,770,000Free FloatN/AMarket Cap$163.69 million OptionableNot Optionable BetaN/A 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:NGENF) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share NervGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.